Navigation Links
Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
Date:8/4/2008

eutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the progress, timing and outcomes of ongoing discussions with regulatory authorities and the potential progress, timing and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation:
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
2. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
3. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
4. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
5. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
10. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
11. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Hologic, Inc. (NASDAQ: ... and Chief Executive Officer, will present at the Morgan Stanley ... , New York on Tuesday, September ... parties are invited to listen to the live audio webcast ... at www.hologic.com/investors-overview . An archive of the presentation will ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced an update on corporate and ... structure, commitment for future funding, ongoing clinical ... In corporate news, Chief Executive Officer ...
(Date:9/2/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a ... XIAFLEX ® in the U.S. and XIAPEX ® ... Wegman , will present at the following upcoming investor conferences. ... & Renshaw 16 th Annual Global Investment Conference ... 9, 2014 at 9:10 a.m. EDT , Aegis ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2
... (NASDAQ: AMRI ), a global contract services organization ... as part of its ongoing global operations review to improve ... its European operations focused on a reduction of the workforce ... at its Budapest, Hungary operation. As a ...
... Jan. 9, 2012  Xenon today announced a strategic alliance ... RO, ROG; OTCQX: RHHBY), to discover and develop compounds ... "We are delighted to be collaborating with ... "Genentech is among the world,s leading biotech companies and ...
Cached Medicine Technology:AMRI Announces Review of Its Hungary Operation 2AMRI Announces Review of Its Hungary Operation 3Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics 2
(Date:9/2/2014)... September 02, 2014 The new ... to reduce discomfort and fatigue by absorbing stress and ... eco-friendly, renewable bio-foam core, these anti-fatigue mats are intended ... According to a study by the Texas A&M University, ... difference in reducing spinal compression and increase in sit-reach ...
(Date:9/2/2014)... A little white pill may help scientists learn why ... their peers, even if their lungs are relatively healthy. ... marketed as Revatio to treat pulmonary hypertension and Viagra ... of over-the-counter antioxidants will help them identify the root ... for these patients. , "We want to understand ...
(Date:9/2/2014)... increasing concern to health officials both in NYC and ... Health and Mental Hygiene, the number of unintentional opioid-involved ... of such deaths in 2000. Much of the increase ... prescription opioid (PO) use among teens and young adults, ... transitioned from POs to heroin. , Now researchers ...
(Date:9/2/2014)... new guideline, the Society for Maternal-Fetal Medicine has recommended ... , "There is no evidence that bed rest ... Center for Maternal and Fetal Medicine and one of ... that bed rest can be harmful for moms, babies, ... are placed on bed rest during their pregnancy. Surveys ...
(Date:9/2/2014)... -- Many people believe that marijuana is not addictive, ... more people are able to obtain and consume cannabis ... people are less likely to perceive it as addictive ... Massachusetts General Hospital,s Center for Addiction Medicine, said in ... cannabis use can have significant consequences, and we know ...
Breaking Medicine News(10 mins):Health News:New Eco-Pro Premium Anti-fatigue Mats from Martinson-Nicholls Prevent Fatigue and Discomfort for Standing Workers 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3Health News:SMFM releases paper on activity restriction in pregnancy 2Health News:'Pot Addiction' May Be Real, Study Suggests 2
... Alan Mozes HealthDay Reporter , WEDNESDAY, July 20 ... shorter people to develop cancer, new British research says. ... cancer, leukemia or melanoma appears to go up about 16 ... "Taller women in our study had increased risk of ...
... Neurologist Michele Tagliati, MD, director of the Movement ... an elite international task force commissioned by the ... on deep brain stimulation for dystonia, an uncommon ... The resulting articles, describing the data ...
... , WEDNESDAY, July 20 (HealthDay News) -- In a ... Wednesday approved the blood thinner Brilinta (ticagrelor) for use ... their odds for heart attack and death. Acute ... or heart attack linked to lowered blood flow to ...
... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay News) -- ... disease as a major health threat, fearing its onset nearly ... Germany, Poland, Spain and the United States, the poll also ... to visit a doctor if they or a loved one ...
... Reporter , WEDNESDAY, July 20 (HealthDay News) -- The race ... New technology promises to cut costs while speeding the amount ... and potentially provide a personalized report of health risks and ... was first mapped in 2001 and cost roughly $1 billion ...
... (HealthDay News) --, Liars can control certain facial expressions when ... time, a new study shows. The researchers noted the ... conducting the study, scientists randomly asked 60 people to either ... pair of movie tickets from an envelope. While being interviewed, ...
Cached Medicine News:Health News:Study Contends Taller People at Heightened Cancer Risk 2Health News:Study Contends Taller People at Heightened Cancer Risk 3Health News:Cedars-Sinai movement disorders expert on international task force for dystonia treatment 2Health News:Cedars-Sinai movement disorders expert on international task force for dystonia treatment 3Health News:Cedars-Sinai movement disorders expert on international task force for dystonia treatment 4Health News:FDA Approves Blood Thinner Brilinta for Heart Patients 2Health News:International Poll Shows Many Fear Alzheimer's as Much as Cancer 2Health News:International Poll Shows Many Fear Alzheimer's as Much as Cancer 3Health News:Cheaper DNA Sequencing Coming Closer 2Health News:Cheaper DNA Sequencing Coming Closer 3Health News:Scrutinizing Faces Might Catch Liars, Study Finds 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: